Aggregated News
It has a license to one of the biggest scientific advances in history, and its rivals have made big money on Wall Street with splashy public offerings. But CRISPR Therapeutics, the quietest member of an exclusive club with the rights to turn gene-editing technology into medicine, seems content to keep its work secret, disclosing little about its targets or timelines. At least for now.
As its name would suggest, CRISPR Therapeutics is working in the booming field of, well, therapeutics with CRISPR — a powerful genetic tool that allows scientists to find and replace the errant strands of code behind certain ailments. The science behind the technique first came to light just four years ago, but its rapid progression has researchers buzzing about future cures for muscular dystrophy, malaria, and a host of rare diseases.
All three companies that have licensed the technology — Editas Medicine, Intellia Therapeutics, and CRISPR Therapeutics — have their R&D operations in Kendall Square, about a mile apart from each other. ...
Image via Flickr